Visit Lucid news for the latest in psychedelics
The impact of psychedelic substances is felt across many aspects of society, both acknowledged and unacknowledged.
To learn best practices developed by harm reduction experts for the novice and intrepid psychonaut alike, start here.
Iconic moments in pop culture, tech innovation, and art have been inspired by psychedelics
Psychedelics have a long, rich tradition of ceremonial use and the potential to elicit spiritual experiences
No, but clinical trials for MDMA-assisted psychotherapy to treat PTSD may lead to FDA approval in the U.S. in 2024.
LSD was first synthesized in 1938 by Swiss chemist Albert Hofmann, while he attempted to develop a stimulant to treat respiratory issues.
MDMA was first synthesized in 1912 by the German pharmaceutical company Merck, and rediscovered by chemist Alexander (Sasha) Shulgin in the 1970s.
Cultivating a proper set and setting – one’s mental state and physical environment – is a crucial part of preparing for any psychedelic experience.
Ketamine first entered the party scene in the 1970s, which led to it being labeled a “party drug,” and particularly popular within rave and club cultures.
Search Psychedelic U to learn and discover.
UPDATED: July 21st, 2023
MDMA has been classified as a Schedule I drug under the US Controlled Substances…
UPDATED: July 21st, 2023
Ketamine was developed in 1962 by chemist Calvin Stevens for Parke-Davis Company (today, a…
UPDATED: July 21st, 2023
Magic mushrooms have been used for the purpose of connecting with the divine by…
UPDATED: July 21st, 2023
The Drug Enforcement Agency classifies ketamine as a Schedule III drug under the Controlled…
UPDATED: July 21st, 2023
LSD has long been associated with enhancing creativity and promoting divergent thinking. Many artists,…
UPDATED: July 20th, 2023
It is likely that people have ingested magic mushrooms for millennia. Ancient drawings and…
The Drug Enforcement Administration has released two notices in the Federal Register declaring plans over the next year to expand the production of psilocybin, psilocin, and ibogaine for use in new research and clinical trials.
Prior to last week’s FDA decision to reject Lykos Therapeutics’ proposed MDMA-assisted therapy for PTSD, Rep. Jack Bergman (R-MI) reflected on the urgent need for better PTSD treatments to reduce veteran suicides and the game plan for lawmakers to keep support for psychedelic-assisted therapies moving forward.
80 members of Congress sign letters of support for MDMA-AT, including those from states with psychedelic access on the ballot.